Space Foundation Names Aspen Laser Systems, LLC as Space Certification Program Partner

February 8, 2021

Space Foundation, a nonprofit advocate organization founded in 1983, today announced Aspen Laser Systems, LLC as the most recent company to become a Space Certification partner.

Aspen Laser Systems has adapted a technology originally developed for NASA into a method of delivering noninvasive and painless light-based photobiomodulation (PBMT) therapy treatment for conditions such as arthritis, tendonitis, and acute joint or muscle injuries.

Space Certification Program awards a “seal of approval” to commercial companies that demonstrate products and services in technology, data, education and creative markets that originate from space technology and are a source of inspiration for discoveries and innovations in the global space ecosystem. Today, every community, infrastructure, and aspect of modern life is either profoundly dependent on or indirectly affected by space-related innovations.

Aspen Laser President Charles Vorwaller commented on the partnership saying, “Aspen Laser is extremely proud of our new relationship with Space Foundation. Our company and products will benefit greatly from this unique recognition, and we firmly believe that our consistent use of the Space Certification Program and official seals will expand the awareness of photobiomodulation. The Aspen Laser products are a great addition for any healthcare professional, whether experienced or just starting out with photobiomodulation.”

Carah Barbarick, space awareness programs manager at Space Foundation, also shared, “Aspen Laser Systems is an exciting addition to our Space Certification partners. With a focus on raising the standards in medical care, they are using space technology to improve the lives of all their patients, both human and animal.”

Therapeutic Technology Developed for NASA Evolved for Clinical Use

The National Aeronautics and Space Administration (NASA) became involved in research utilizing light therapy beginning in the 1990s, with many of these findings being a springboard for additional scientific and clinical studies. In 1993, Quantum Devices, Inc. developed an LED for NASA to use in their plant growth experiments. These experiments demonstrated that red LED wavelengths could boost plant growth. Coincidentally, the scientists noticed that their own skin lesions began to heal faster as well. NASA subsequently began to study the use of LED and infrared wavelengths to increase the metabolism of human cells and for medical uses to improve healing for astronauts in space.

Many medications (RX and OTC) and therapy products treat symptoms that only provide temporary relief or short-term benefits. In contrast, PBMT is a preferable treatment because it provides energy through specific wavelengths of light that penetrate inside the body and into damaged and unhealthy cells, triggering a chemical response within the cells that result in stimulating the body to heal itself.

Aspen Laser Systems, LLC was founded by Vorwaller in 2014 with the mission to provide technology for medical doctors and therapists to use in helping their patients with better pain management and a faster recovery. Aspen Laser is an FDA-registered medical device company specializing in photomedicine with a unique focus and expertise in photobiomodulation which is an alternative to pharmaceuticals and other therapeutic modalities.

According to Vorwaller, “We became aware of the research that NASA was doing in the early 1990s initially using LED low level light therapy. Today, the Aspen Laser products are the result of an evolution from this early technology. Over time, we increased the power level of the diodes, added additional infrared wavelengths, and concentrated the light output, resulting in targeted laser therapy that provides a higher concentration of light energy into an area of the body that requires it, due to localized pain or injury.”

Aspen Laser Systems’ national headquarters is based in Lindon, Utah, with an additional location in Ft. Pierce, Florida.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”